Talking therapies linked with reduced risk of cardiovascular disease Mindbody medicine Read the full article here
Quality of Life 5 Years Following Transfemoral TAVR or SAVR in Intermediate Risk Patients: john doe 5 April 30, 2024
Timing of Complete Multivessel Revascularization in Patients Presenting With Non-ST-Segment Elevation Acute Coronary Syndrome: john doe 5 April 30, 2024
Prognostic Implications of Microvascular Resistance Reserve in Symptomatic Patients With Intermediate Coronary Stenosis: john doe 5 April 30, 2024
Angiographic Coronary Slow Flow Is Not a Valid Surrogate for Invasively Diagnosed Coronary Microvascular Dysfunction: john doe 5 April 30, 2024
New Approaches to Assessment and Management of Tricuspid Regurgitation Before Intervention: john doe 5 April 30, 2024
Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure: john doe 5 April 30, 2024
Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure: john doe 5 April 30, 2024